Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Early diagnosis of Parkinson's disease (PD) continues to be a major challenge in the field. The lack of a robust biomarker to detect early stage PD patients has considerably slowed the progress toward the development of potential therapeutic agents. We have previously evaluated several RNA biom...
Main Authors: | Jose A Santiago, Judith A Potashkin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4643881?pdf=render |
Similar Items
-
Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
by: Jose A. Santiago, et al.
Published: (2018-05-01) -
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
by: Jose A. Santiago, et al.
Published: (2014-10-01) -
Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease.
by: Marina Picillo, et al.
Published: (2017-01-01) -
Plasma catecholamine levels in the early stages of treatment-naïve Parkinson’s disease
by: Z. A. Zalyalova, et al.
Published: (2018-12-01) -
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
by: Jose A Santiago, et al.
Published: (2014-01-01)